Chronic Hepatitis B: management update.
|
|
- Jordan Thomas
- 6 years ago
- Views:
Transcription
1 Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011.
2 Background epidemiology Chronic hepatitis B (CHB) is an important public health problem & a leading cause of liver related morbidity & mortality worldwide (Lee WM, Hepatitis B virus infection. N Engl. J. Med. 1997, 337: ) In the USA an estimated 1.25 million individuals (0.4%) of the population are infected with hepatitis B virus. ( McQuillan GM et al Am J. Public Health 1999,89:14 18) In Kenya the HBsAg carrier rate is about 10%(Okoth e tal)
3 CHB: Disease progression If unrx. individuals with hepa s B are at risk of developing: Liver cirrhosis Hepatic decompensation HCC Cumulative rate of morbidity & mortality from cirrhosis & HCC is highest in those who acquire HBV infection as neonates or in early childhood. (Lee WM. N. Engl. J Med. 1997, 337: )
4 CHB: Natural history/phases of HBV infection Immune tolerance Immune clearance Inactive carrier Resolution Reactivation (Chu CM et al. Current hepatitis reports 2004:3: Yim HJ. Et al. Hepatology 2006;43:s173 s181.)
5 CHB: What defines the Phases. Immune tolerance: ALT: Normal or minimally HBV DNA: High levels >20,000 Iu/ml (> 10 5 copies/ml) HBeAg +ve., anti. Hbe ve. Liver Histology: Minimal activity: absent or scant fibrosis
6 CHB: What defines the Phases. Immune tolerance phase Note : Acquisition of HBV at birth or early childhood is associated with: a long latency period of immune tolerance, which might last for 2 3 decades before immune clearance, characterized by HBeAg seroconversion to antibody to HBeAg ( anti. Hbe) Late acquisition is associated with a very short immune tolerance phase or none at all. (Chu CM et al. Current hepatitis reports 2004:3: ( Lai CL et al Ann Intern Med 2007;147:58 61)
7 CHB: What defines the Phases. Immune clearance: ( HBeAg +ve CHB) ALT: Persistently or intermi ently Serum HBV DNA > 20,000 Iu/ml Liver histology: Active with necroinflammation score 4. HBsAg +ve. >6months
8 CHB: What defines the Phases. Inactive carrier:( HBsAg > 6months) HBsAg +ve. & IgG anti HBc +ve ALT normal HBV DNA low or undetectable ( <2000Iu/ml.) HBeAg ve. anti. Hbe +ve. Liver histology: Inactive with minimal fibrosis & necroinflamation score <4.
9 CHB: What defines the Phases. Reactivation HBeAg ve. CHB, ant. HBe +ve. & HBsAg +ve. HBV DNA ( > 2000 Iu/ml) ALT Fluctua ng Resolution (HBsAg ve.) ALT : Normal HBeAg ve. Anti Hbe +ve. HBV DNA ve. In serum, Low levels might be detected in the liver, in form of covalently closed circular DNA (cccdna) Liver histology inactive.
10 CHB: Risk factors for disease progression Viral factors HBeAg +ve :Hazard ratio(hr) 4.2 HBV DNA level > 2000Iu/ml: HR 2.7 >20,000Iu/ml: HR Host factors: Male gender: HR 3.0 Advanced age(>35): HR Alcohol consumption: HR 2.6 Cigarette smoking HR 1.7
11 CHB: Risk factors for disease progression Other factors: Co infection with HCV,HDV,or HIV HBV genotype: Worse with genotype C Presence of HBV precore & especially core promoter mutation ALT elevation: ( Severity & Frequency )
12 CHB: Patient evaluation: History: e.g. F/H of :HBV infection, liver cancer Risk factors for co infection Alcohol use
13 CHB( HBsAg +ve >6months): Patient evaluation: Laboratory: Liver biochemistry (ALT, Albumin, PTI) Anti. HBc. ( IgG, IgM) HBeAg, anti HBe Markers of HBV replication: (HBV DNA) Check for co infection: HCV(anti HCV), HDV( anti HDV) HAV(IgM. anti HAV) HIV HBV Genotype in selected cases. TBC & Urinalysis & U/E + creatinine. Alfa feto protein
14 CHB: Patient evaluation: Imaging Abdominal ultrasound CT scan MRI Fibroscan: If available: Evaluates degree of fibrosis Liver biopsy
15 CHB: Patient evaluation: Liver biopsy: Indications: Pa ents with intermi ent or persistent in ALT Pts. With elevated serum HBV DNA (HBeAg +ve. >20,0000Iu/ml: HBeAg ve: >2000Iu/ml.) but normal ALT particularly if >35yrs of age Mass lesion
16 ALT: CHB: Patient evaluation: Practical points. NOTE : Cut off level of upper limit of normal in pts. With CHB is lower than for commercial level. Males: 30 Iu/ml Females: 19 Iu/ml
17 CHB: Patient evaluation: Practical points. HBV DNA: Serum HBV DNA must be done in all pts. With CHB It is a direct measure of viral replication It characterizes the state of replication It predicts the risk of cirrhosis, liver decompensation & HCC. This is x4 fold if HBeAg is +ve. (Liaw YF et al Liver Int 2006;26:23 29, de Jorgh FE et al Gastroenterology 1992;103: ) ( 1Iu/ml = 5 6 copies/ml )
18 CHB: Patient evaluation: Practical points. HBV Genotype Influences : +ve progression of disease Risk of HCC Response to therapy Genotype B: Associated with early HBeAg seroconversion at an early age Genotype C: Associated with severe disease progression & HCC Genotype A&B: Associated with better response to therapy ( Pegylated INF but not Nucleos(t)ide analogue)
19 CHB: Interpretation of serological tests:(some aspects) Chronic hepatitis HBsAg +ve > 6 months & IgG anti HBc +ve. The onset of CHB infection is marked by continual presence of HBsAg, High serum levels of HBV DNA & +ve HBeAg in serum.
20 CHB: Interpretation of serological tests:(some aspects) Occult hepatitis HBsAg ve, IgG anti HBc +ve. HBV DNA +ve at low levels <2000Iu/ml Resolved hepatitis: HBsAg ve., anti HBs +ve. anti HBc +ve. Vaccinated recipient: HBsAg ve. anti HBs +ve, anti HBc ve., (Emmet B Keeffe et al.clinical Gastroenterology & hepatology 2008;6: )
21
22 CHB: Goal of Therapy 1. Eliminate or significantly suppress the replication of CHB (HBV DNA suppression to possible lowest level) This leads to : ALT normalization & histological improvement THUS Prevent the progression of liver disease to cirrhosis, decompensation, HCC (Emmet B Keeffe et al.clinical Gastroenterology & hepatology 2008;6: )
23 CHB: Goal of Therapy 2. HBeAg loss with seroconversion to anti Hbe. in pts. Who are HBeAg +ve at the initiation of Rx. The complete HBeAg seroconversion indicates a high likelihood that the benefit will persist once the patient is off therapy. Note: continue Rx. For at least 6months after seroconversion if on NA. (Emmet B Keeffe et al.clinical Gastroenterology & hepatology 2008;6: ) (Lok As Hepatology 2009;50: )
24 CHB: Goal of Therapy 3. HBsAg loss: This would be a Rx. End point in pts. Who are HBeAg ve at the initiation of therapy However this is rarely achieved, hence an unrealistic goal. Thus pts who are HBeAg ve should be treated for life if on NA (Emmet B Keeffe et al.clinical Gastroenterology & hepatology 2008;6: ) (Lok As Hepatology 2009;50: )
25 CHB: Drug therapy What drugs are available: 7 drugs are currently available Interferon α 2b 5 10 mu/dose x3/wk. Peg Interferon α 2a 180µg s/c/wk. Lamivudine 100mg P.O. OD Adefovir 10mg/day PO OD Entecavir 0.5mg 1.0mg/day PO, OD Telbivudine 600mg OD PO Tenofovir 300mg OD PO (Lok AS et al Hepatol 2009; 50: )
26 CHB: Drug therapy What is the current recommended 1 st. Line therapy: Peg Interferon alfa 2a Exception: Pregnancy, chemotherapy prophylaxis,decompensated cirrhosis, acute infection Entecavir Tenofovir (EASL. J hepatol 2009;50: , Liaw F et al Hepatol int. 2008; 2: , Lok AS et al Hepatol 2009;50: )
27 CHB: Drug therapy NOTE: Lamivudine : Has been removed from the list of preferred 1 st. Line drugs because of high rate of resistance (Keeffe EB,et al Clin Gastroenterol Hepatol 2006;4: ; Lai CL et al N Engl J Med 2007;357: ; Keeffe EB et al Clin Gastroenterol Hepatol 2008;6: )
28 CHB: Who to treat 1. Pt. Who is HBsAg With: HBV DNA 20,000 Iu/ml & Normal ALT Should have a liver biopsy done particularly if >30yrs. Of age If histology is: Stage 2 &/or grade 2 necroinflammation. TREAT NOTE: Pt.<30yrs. Liver biopsy is optional as is in immune tolerance phase of infection & is unlikely to have significant disease & responds poorly to Rx.
29 CHB: Who to treat 2. ALT > ( 1 2 xuln) with: HBV DNA 20,000 Iu/ml ( HBeAg +ve.) 2000Iu/ml (HBeAg ve.) TREAT even without liver biopsy
30 CHB: Who to treat 3. HBeAg +ve or ve with : underlying cirrhosis or HIV co infection TREAT If HBV DNA 2000Iu/ml
31 CHB: Who not to treat. 1. High HBV DNA & Normal ALT Particularly if <35yrs of age: They tend to be in immune tolerance phase, thus have minimal disease activity on liver biopsy. Those >35yrs. Do liver biopsy & Rx. If significant stage & / or grade NOTE: Always consider ALT levels in conjunction with serum HBV DNA & Pts. Age.
32 CHB: Treatment end point: Nucleoside/Nucleotide analougue 1. HBeAg +ve: Rx. Until : HBeAg seroconversion + Undetectable HBV DNA by PCR Then continue for a further 6 12 months. Rx. For life if no sero conversion 2. HBeAg ve: HBV DNA undetectable, ALT normal HBsAg loss end point is rare so is unrealistic Hence Rx. Is life long
33 CHB: Treatment end point: Peg Interferon Duration is 1yr. Effect continues after stopping Rx. NOTE: Despite prolonged HBV DNA suppression relapse is common unless there is loss & seroconversion of HBsAg This effect is better with PEG Interferon> NA.
34 CHB: When to consider PEG INF Favourable predictors of response: Lower baseline HBV DNA < 10 9 copies/ml High ALT Genotype A&B
35 CHB: When to consider PEG INF Specific patient demographics Young ( particularly females intending to be pregnant in the near future) Absence of Comorbidities Patient preference Concomitant HCV infection
36 CHB: When not to consider PEG INF Patients with Cirrhosis, particularly when decompensated Pregnancy Immunosuppressed pts. Lange CM et al Hepatology 2009;50: Lok AS et al Hepatology 2010;52:743 47
37 Cumulative rates of resistance with oral agents in Nucleos(t)ide naive pts. Drug Resistance Rate 1 st. Generation Yr1 Yr2 Yr3 Yr4 Yr5 Lamivudine 24% 38% 49% 67 70% 2 nd. Generation Adefovir 0% 3% 11% 18% 29% Telbivudine 4% 17% 3 rd. Generation Entecavir 0.2% 0.5% 1.2% 1.2% 1.2% Tenofovir 0% 0% 0% EASL J Hepatol. 2009; 50: , Healthcole E et al AASLD 2009; Abstract 48
38 None exists Resistance:Pegylated INF
39 CHB: Management of antiviral resistance Lamivudine Restance: Add adefovir OR tenofovir Stop LAM & switch to Tenofovir/Emtricitabine. Adefovir Resistance Add LAM OR Entecavir Stop adefovir & switch to Tenofovir/Emtricitabine
40 CHB: Management of antiviral resistance Entecavir Resistance: Switch to Tenofovir *Tenofovir/Emtritabine Telbivudine Resistance: Add adefovir or Tenofovir Stop Telbuvidine & switch to *Tenofovir/Emtricitabine Lok AS Hepatology 2010;52:
41 CHB: Management of antiviral resistance NOTE: Ac vity of Entecavir is in LAM/Telbuvidine resistance Ac vity of Tenofovir is in Adefovir resistance Lok AS Hepatology 2010;52:
42 CHB: Management of antiviral Tenofovir: No resistance resistance HIV co infected Pts. Use Tenofovir/Emtricitabine ( Truvada) Lok AS et al Hepatol 2009;50:61 62
43 CHB: Management of antiviral resistance When possible, it is most beneficial to use the most potent nucleos(t)ide analogue that posses the lowest risk of genotype resistance as initial therapy for pts. With nucleos(t)ide naive disease. The development of resistance is associated with loss of initial response & HBV DNA rebound which is followed by biochemical breakthro, & eventual reversion of histological improvement.
44 Pegylated Interferon Entecavir Tenofovir CHB:1 o Drugs Tenofovir/Emtricitabine (TRUVADA) in HBV/HIV co infected pt.
45 CHB: Special Population Groups. Cirrhosis: Compensated: Viral load 2000Iu/ml Preferred therapies: Entecavir & tenofovir NAs preferred over IFN as the latter can be associated with hepatic flares Long term Rx. Preferred Lok As et al Hepatology 2009; 50:
46 CHB: Special Population Groups. Decompensated Cirrhosis R x. If there is any detectable HBV DNA Tenofovir or Entecavir monotherapy (Alt. LAM or Telbuvidine + Adefovir or Tenofovir) Liver transplant INF is C/I Life long Rx. Is recommended Lok AS et al. Hepatology 2009;50:
47 CHB: Special Population Groups. HBV/HIV Co infected HBV Rx.Indicated BUT HIV (HAART) not indicated HBeAg ve.: Adefovir 10mg OD HBeAg +ve : Consider PEG INF IF Fails Adefovir Choose drug (NA) with no effect on HIV Telbivudin not recommended because of HBV resistance rate Lok As et al Hepatology 2009;50:
48 CHB: Special Population Groups. HBV/HIV Co infection HAART Indicated BUT HBV Rx. Not indicated: Choose anti HIV drugs with no effect on HBV
49 CHB: Special Population Groups. HBV/HIV Co infection HAART & HBV ( HBV DNA 2000Iu/ml) treatment Indicated. Choose drug with dual activity Preferred: Tenofovir + LAM or Emtricitabine Entecavir not recommended as is associated with induction of HIV resistant mutation
50 END THANK YOU
Management of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationThe natural course of chronic HBV infection can be divided into four, which are not always continuous.
HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationProfessor Vincent Soriano
Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,
More informationConsiderations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection
Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection Mahnaz Arian, MD Assistant Professor in infectious Disease Mashhad university of Medical
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationLandmarks for Prevention and Treatment
HBeAg-positive chronic hepatitis B Why do I treat my patient with a nucleos(t)ide analogue? Dr. Nancy Leung BSc(Lon) MSc(Lon) MBBS(Lon) MD(Lon), FRCP(Lon) FRCP(Edin) FHKCP FHKAM Consultant Physician, Alice
More informationMANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman
MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT Professor Salimur Rahman Department of Hepatology, BSMMU President, Association for the study of the liver, Dhaka,
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationClinical Case Maria Butí, MD, PhD
Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with
More informationHepatitis B in HIV Patients. Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center
Hepatitis B in HIV Patients Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center Learning Objectives Identify tests to diagnoses HBV active infection, resolved infection, and need for immunization
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationGish RG and AC Gadano. J Vir Hep
Treatment in Hepatitis B and C There are options! Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Hepatitis B Virus Epidemiology and natural history 400
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationTerapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri
Terapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri Nicola Coppola Dipartimento di Salute Mentale e Medicina Preventiva Seconda Università di Napoli Main goal of treatment of chronic
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationGAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation
VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationHBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue?
4 th PARIS HEPATITIS CONFERENCE HBeAg-negative chronic hepatitis B Why do I treat my chronic hepatitis B patients with a nucleos(t)ide analogue? George V. Papatheodoridis, MD 2nd Department of Internal
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationDelta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne
Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis treatment in 2018 Currently, Peg-IFNα 180 µg/wk is the only effective treatment
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationNorth Africa) The prevalence of CHB varies widely across EMEA (Europe, Middle East & 8% High 2 8% Intermediate <2% Low
The prevalence of CHB varies widely across EMEA (Europe, Middle East & North Africa) 8% High 2 8% Intermediate
More informationViral hepatitis Prevention Board. Clinical aspects of hepatitis B
Viral hepatitis Prevention Board Clinical aspects of hepatitis B Natural History and serological markers acute and chronic hepatitis B Acute hepatitis B Immune response Immunological tolerance Resolution
More informationGUIDELINE. South African guideline for the management of chronic hepatitis B: 2013
South African guideline for the management of chronic hepatitis B: 2013 C W N Spearman, 1 MB ChB, FCP (SA), MMed, PhD; M W Sonderup, 1,2 MB ChB, BPharm, FCP (SA); J F Botha, 2,3 MB ChB, FCP (SA); S W van
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationViral hepatitis in reproductive health. Pierre Jean Malè. Training in Reproductive Health Research - Geneva 2006
Viral hepatitis in reproductive health Pierre Jean Malè Training in Reproductive Health Research - Geneva 2006 15.03.2006 HBV and HCV treatment Pierre-Jean Malè MD 15.03.2006 Global Impact of Hepatitis
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationPrimary Care for Hepatitis B and C:
Primary Care for Hepatitis B and C: Clinical Tools for Efficient Management Estimated 17 Million Persons With HCV Infection Worldwide 3-4 million newly infected each yr worldwide Advances in Internal Medicine
More informationNew therapeutic perspectives in HBV: when to stop NAs
Liver International ISSN 1478-3223 REVIEW ARTICLE New therapeutic perspectives in HBV: when to stop NAs Cristina Perez-Cameo, Monica Pons and Rafael Esteban Liver Unit, Department of Internal Medicine,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationIs there a need for combination treatment? Yes!
18.0.2012 C Hep Meeting Berlin Is there a need for combination treatment? Yes! Florian van Bömmel University Hospital Leipzig Hepatology Section Germany Most patients respond to monotherapy with entecavir
More informationA Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update
Accepted Manuscript A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update Paul Martin, MD, Daryl T.-Y. Lau, MD, MSc, MPH, Mindie H. Nguyen, MD,
More informationA 20 year-old university student Known chronic HBV infection since he was 12 year-old.
Case 1 A 20 year-old university student Known chronic HBV infection since he was 12 year-old. His father died from HCC. Two of his 3 brothers also have chronic hepatitis B Still asymptomatic with persistent
More informationManagement of hepatitis B virus
Journal of Antimicrobial Chemotherapy Advance Access published May 14, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn188 Management of hepatitis B virus Nidhi A. Singh and Nancy Reau* Section
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationChronic Hepatitis B. What every GP should know. Prof Ed Gane NZ Liver Unit
Chronic Hepatitis B What every GP should know Prof Ed Gane Z Liver Unit Case 1 55 Yr old Tonga male»well but dad died of liver cancer»lfts: ALT 85, GGT 60; ALP 75; bilirubin 12 What next? Case 1 55 Yr
More informationWhats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen
Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationEmerging Challenges In Primary Care: Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor
More informationViral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP
Viral Hepatitis Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP Viral hepatitis Viral hepatitis must be considered in any patient presenting with hepatitis on LFTs (high
More informationPerspective Hepatitis B Virus Infection: What Is Current and New
Perspective Hepatitis B Virus Infection: What Is Current and New Hepatitis B virus (HBV) infection is a lifelong dynamic disease that can be controlled with treatment but cannot yet be cured. Risk of end-stage
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More informationWhat can the challenges we face? HBV: Long term NUC treatment
LUNCH WORKSHOP 30th January from 12:30 to 14:30 Future therapies for HBV and HDV: What can we expect? What can the challenges we face? HBV: Long term NUC treatment Massimo Levrero Cancer Research Center
More informationTreatment of hepatitis B
Treatment of hepatitis B Prof. Dr. Cihan Yurdaydin University of Ankara Medical School Department of Gastroenterology 2 nd CEE Meeting on Viral Hepatitis and Co-infection with HIV Bucharest, Romania, 6-7
More information